Long-term remission of corticosteroid-resistant Graves' orbitopathy after therapy with tocilizumab
Endokrynol Pol. 2024;75(1):117-118. doi: 10.5603/ep.97224.ABSTRACTNot required for Clinical Vignettes.PMID:38497401 | DOI:10.5603/ep.97224 (Source: Endokrynologia Polska)
Source: Endokrynologia Polska - March 18, 2024 Category: Endocrinology Authors: Joanna Rymuza Aleksander Ku ś Dorota Bia łas-Niedziela Monika Turczy ńska Dariusz K ęcik Tomasz Bednarczuk Source Type: research
Tocilizumab treatment in COVID-19 patients: therapy's side effects and effect on mortality
CONCLUSIONS: Despite the risks of side effects, tocilizumab was used in COVID-19 treatment since it is an interleukin-6 blocker. Although the first publications stated that the treatment could decrease the mortality rate, later meta-analyses did not support these results. Our study also found that using tocilizumab did not make a difference in long-term mortality. We also observed that the known side effects were seen in short-term use.PMID:38497892 | DOI:10.26355/eurrev_202403_35623 (Source: European Review for Medical and Pharmacological Sciences)
Source: European Review for Medical and Pharmacological Sciences - March 18, 2024 Category: Drugs & Pharmacology Authors: P Ayvat S Kayhan Omeroglu Source Type: research
Long-term remission of corticosteroid-resistant Graves' orbitopathy after therapy with tocilizumab
Endokrynol Pol. 2024;75(1):117-118. doi: 10.5603/ep.97224.ABSTRACTNot required for Clinical Vignettes.PMID:38497401 | DOI:10.5603/ep.97224 (Source: Endokrynologia Polska)
Source: Endokrynologia Polska - March 18, 2024 Category: Endocrinology Authors: Joanna Rymuza Aleksander Ku ś Dorota Bia łas-Niedziela Monika Turczy ńska Dariusz K ęcik Tomasz Bednarczuk Source Type: research
Tocilizumab treatment in COVID-19 patients: therapy's side effects and effect on mortality
CONCLUSIONS: Despite the risks of side effects, tocilizumab was used in COVID-19 treatment since it is an interleukin-6 blocker. Although the first publications stated that the treatment could decrease the mortality rate, later meta-analyses did not support these results. Our study also found that using tocilizumab did not make a difference in long-term mortality. We also observed that the known side effects were seen in short-term use.PMID:38497892 | DOI:10.26355/eurrev_202403_35623 (Source: European Review for Medical and Pharmacological Sciences)
Source: European Review for Medical and Pharmacological Sciences - March 18, 2024 Category: Drugs & Pharmacology Authors: P Ayvat S Kayhan Omeroglu Source Type: research
Long-term remission of corticosteroid-resistant Graves' orbitopathy after therapy with tocilizumab
Endokrynol Pol. 2024;75(1):117-118. doi: 10.5603/ep.97224.ABSTRACTNot required for Clinical Vignettes.PMID:38497401 | DOI:10.5603/ep.97224 (Source: Endokrynologia Polska)
Source: Endokrynologia Polska - March 18, 2024 Category: Endocrinology Authors: Joanna Rymuza Aleksander Ku ś Dorota Bia łas-Niedziela Monika Turczy ńska Dariusz K ęcik Tomasz Bednarczuk Source Type: research
Long-term remission of corticosteroid-resistant Graves' orbitopathy after therapy with tocilizumab
Endokrynol Pol. 2024;75(1):117-118. doi: 10.5603/ep.97224.ABSTRACTNot required for Clinical Vignettes.PMID:38497401 | DOI:10.5603/ep.97224 (Source: Endokrynologia Polska)
Source: Endokrynologia Polska - March 18, 2024 Category: Endocrinology Authors: Joanna Rymuza Aleksander Ku ś Dorota Bia łas-Niedziela Monika Turczy ńska Dariusz K ęcik Tomasz Bednarczuk Source Type: research
Tocilizumab treatment in COVID-19 patients: therapy's side effects and effect on mortality
CONCLUSIONS: Despite the risks of side effects, tocilizumab was used in COVID-19 treatment since it is an interleukin-6 blocker. Although the first publications stated that the treatment could decrease the mortality rate, later meta-analyses did not support these results. Our study also found that using tocilizumab did not make a difference in long-term mortality. We also observed that the known side effects were seen in short-term use.PMID:38497892 | DOI:10.26355/eurrev_202403_35623 (Source: European Review for Medical and Pharmacological Sciences)
Source: European Review for Medical and Pharmacological Sciences - March 18, 2024 Category: Drugs & Pharmacology Authors: P Ayvat S Kayhan Omeroglu Source Type: research
Long-term remission of corticosteroid-resistant Graves' orbitopathy after therapy with tocilizumab
Endokrynol Pol. 2024;75(1):117-118. doi: 10.5603/ep.97224.ABSTRACTNot required for Clinical Vignettes.PMID:38497401 | DOI:10.5603/ep.97224 (Source: Endokrynologia Polska)
Source: Endokrynologia Polska - March 18, 2024 Category: Endocrinology Authors: Joanna Rymuza Aleksander Ku ś Dorota Bia łas-Niedziela Monika Turczy ńska Dariusz K ęcik Tomasz Bednarczuk Source Type: research
Tocilizumab treatment in COVID-19 patients: therapy's side effects and effect on mortality
CONCLUSIONS: Despite the risks of side effects, tocilizumab was used in COVID-19 treatment since it is an interleukin-6 blocker. Although the first publications stated that the treatment could decrease the mortality rate, later meta-analyses did not support these results. Our study also found that using tocilizumab did not make a difference in long-term mortality. We also observed that the known side effects were seen in short-term use.PMID:38497892 | DOI:10.26355/eurrev_202403_35623 (Source: European Review for Medical and Pharmacological Sciences)
Source: European Review for Medical and Pharmacological Sciences - March 18, 2024 Category: Drugs & Pharmacology Authors: P Ayvat S Kayhan Omeroglu Source Type: research
Long-term remission of corticosteroid-resistant Graves' orbitopathy after therapy with tocilizumab
Endokrynol Pol. 2024;75(1):117-118. doi: 10.5603/ep.97224.ABSTRACTNot required for Clinical Vignettes.PMID:38497401 | DOI:10.5603/ep.97224 (Source: Endokrynologia Polska)
Source: Endokrynologia Polska - March 18, 2024 Category: Endocrinology Authors: Joanna Rymuza Aleksander Ku ś Dorota Bia łas-Niedziela Monika Turczy ńska Dariusz K ęcik Tomasz Bednarczuk Source Type: research
Tocilizumab treatment in COVID-19 patients: therapy's side effects and effect on mortality
CONCLUSIONS: Despite the risks of side effects, tocilizumab was used in COVID-19 treatment since it is an interleukin-6 blocker. Although the first publications stated that the treatment could decrease the mortality rate, later meta-analyses did not support these results. Our study also found that using tocilizumab did not make a difference in long-term mortality. We also observed that the known side effects were seen in short-term use.PMID:38497892 | DOI:10.26355/eurrev_202403_35623 (Source: European Review for Medical and Pharmacological Sciences)
Source: European Review for Medical and Pharmacological Sciences - March 18, 2024 Category: Drugs & Pharmacology Authors: P Ayvat S Kayhan Omeroglu Source Type: research
Long-term remission of corticosteroid-resistant Graves' orbitopathy after therapy with tocilizumab
Endokrynol Pol. 2024;75(1):117-118. doi: 10.5603/ep.97224.ABSTRACTNot required for Clinical Vignettes.PMID:38497401 | DOI:10.5603/ep.97224 (Source: Endokrynologia Polska)
Source: Endokrynologia Polska - March 18, 2024 Category: Endocrinology Authors: Joanna Rymuza Aleksander Ku ś Dorota Bia łas-Niedziela Monika Turczy ńska Dariusz K ęcik Tomasz Bednarczuk Source Type: research
Tocilizumab treatment in COVID-19 patients: therapy's side effects and effect on mortality
CONCLUSIONS: Despite the risks of side effects, tocilizumab was used in COVID-19 treatment since it is an interleukin-6 blocker. Although the first publications stated that the treatment could decrease the mortality rate, later meta-analyses did not support these results. Our study also found that using tocilizumab did not make a difference in long-term mortality. We also observed that the known side effects were seen in short-term use.PMID:38497892 | DOI:10.26355/eurrev_202403_35623 (Source: European Review for Medical and Pharmacological Sciences)
Source: European Review for Medical and Pharmacological Sciences - March 18, 2024 Category: Drugs & Pharmacology Authors: P Ayvat S Kayhan Omeroglu Source Type: research
Long-term remission of corticosteroid-resistant Graves' orbitopathy after therapy with tocilizumab
Endokrynol Pol. 2024;75(1):117-118. doi: 10.5603/ep.97224.ABSTRACTNot required for Clinical Vignettes.PMID:38497401 | DOI:10.5603/ep.97224 (Source: Endokrynologia Polska)
Source: Endokrynologia Polska - March 18, 2024 Category: Endocrinology Authors: Joanna Rymuza Aleksander Ku ś Dorota Bia łas-Niedziela Monika Turczy ńska Dariusz K ęcik Tomasz Bednarczuk Source Type: research
Tocilizumab treatment in COVID-19 patients: therapy's side effects and effect on mortality
CONCLUSIONS: Despite the risks of side effects, tocilizumab was used in COVID-19 treatment since it is an interleukin-6 blocker. Although the first publications stated that the treatment could decrease the mortality rate, later meta-analyses did not support these results. Our study also found that using tocilizumab did not make a difference in long-term mortality. We also observed that the known side effects were seen in short-term use.PMID:38497892 | DOI:10.26355/eurrev_202403_35623 (Source: European Review for Medical and Pharmacological Sciences)
Source: European Review for Medical and Pharmacological Sciences - March 18, 2024 Category: Drugs & Pharmacology Authors: P Ayvat S Kayhan Omeroglu Source Type: research
